SCI-003 FC-BALANACE

Bendamustine versus Fludarabine/Cyclophosphamide for White Blood Cell Reduction in the Context of CAR-T Cell Therapy: A Randomized Trial

Coordinating Investigator

  • Benjamin Kasenda

    Benjamin Kasenda

    SI

There are various options for treating large B-cell lymphoma. One of them is CAR-T cell therapy. In this procedure, specific immune cells (T cells) are filtered out of the patient’s blood. In the laboratory, the T cells are multiplied and modified so that they can attack cancer cells. The modified T cells (CAR-T cells) are then administered to the patient via infusion, and once inside the patient’s body
destroy the cancer cells.


Before the CAR-T cells can be administered, it is necessary to undergo a course of treatment lasting two to three days. This destroys many white blood cells in the body and increases the likelihood that the CAR-T cells will be able to fight the lymphoma cells over a longer period of time. The active ingredients fludarabine and cyclophosphamide are typically used for this therapy.


This study investigates whether the treatment can also be administered using the active ingredient bendamustine. It is hoped that bendamustine will cause fewer side effects than fludarabine and cyclophosphamide. Bendamustine is already approved in Switzerland for the treatment of cancer.

Intervention Studied

In the study, participants are randomly assigned to two groups:

  • Participants in Group 1 receive bendamustine therapy prior to the CAR-T cell infusion. Bendamustine is administered as an infusion on days 4 and 3 before the CAR-T cell infusion. The bendamustine infusion lasts 30–60 minutes.
  • Participants in Group 2 will receive treatment with fludarabine and cyclophosphamide prior to the CAR-T cell infusion. Both drugs will be administered as infusions on days 5, 4, and 3 before the CAR-T cell infusion. The fludarabine infusion takes about 30 minutes, and the cyclophosphamide infusion takes 30–60 minutes.

A few days after treatment, all study participants will receive an infusion of CAR-T cells. Follow-up visits will last about one year.

Inclusion Criteria

To participate in the study, a person must meet the following requirements:

  • The participant has large-cell B-cell lymphoma and has already been treated for this disease at least once.
  • The participant is scheduled to receive CAR-T cell therapy.
  • The participant is over 18 years of age.

Exclusion Criteria

Individuals who meet any of the following criteria are not eligible to participate in the study:

  • Use of an experimental drug during the four weeks prior to chemotherapy.
  • CAR-T cell therapy within the 12 months prior to chemotherapy.
  • Use of bendamustine in the three months before the T cells are collected for CAR-T cell therapy.

Hospitals

  • HOCH Health Ostschweiz - Kantonsspital St. Gallen
    HOCH Health Ostschweiz - Kantonsspital St. Gallen
  • Kantonsspital Aarau AG
    Kantonsspital Aarau AG
  • Kantonsspital Graubünden
    Kantonsspital Graubünden
  • Luzerner Kantonsspital AG
    Luzerner Kantonsspital AG

Further Studies: Lymphomas

EMCL-Registry

Creation of a European mantle cell lymphoma registry

Recruitment completed

SAKK 38/23 LIBERTY

Non-Hodgkin B-cell lymphoma

Recruitment completed

HOVON 127/ SAKK 37/16

Phase III study comparing R-CODOX-M/R-IVAC versus dose-adjusted EPOCH-R (DAEPOCH-R) for patients with newly diagnosed high risk Burkitt lymphoma

Recruitment completed

IELSG-37

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymphoma (PMLBCL).

MorningLyte

MORNINGLYTE: international, multicenter phase III study to evaluate the efficacy and tolerability of mosunetuzumab in combination with lenalidomide compared to standard treatment in patients with previously untreated follicular lymphoma.

NX-5948-301

NX-5948-301 A Phase I study to determine the best dose(s) for the treatment of adult patients with B-cell lymphoma or leukemia who have relapsed and/or have not responded to other treatment with the investigational compound NX-5948, which degrades the enzyme Bruton's tyrosine kinase.

Recruitment completed

SAKK 38/19

SAKK 38/19 Therapy adjustment based on PET/CT and circulating tumor DNA in patients with diffuse large B-cell lymphoma

Recruitment completed

IELSG-47

MALIBU trial – Phase II study of combination ibrutinib and rituximab in untreated marginal zone lymphomas

IELSG-48

Phase 3, interventional, multicentre, open-label, randomized study comparing rituximab plus zanubrutinib to rituximab monotherapy in previously untreated, symptomatic splenic marginal zone lymphoma (RITZ)

CLL18

Comparison of three therapies in patients with previously untreated chronic lymphocytic leukemia (CLL) or small cell lymphocytic lymphoma (SLL)